Manufacturer of Controlled Substances Notice of Registration, 77067 [E6-21872]

Download as PDF Federal Register / Vol. 71, No. 246 / Friday, December 22, 2006 / Notices Dated: December 14, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–21873 Filed 12–21–06; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances Notice of Registration By Notice dated August 15, 2006, and published in the Federal Register on August 22, 2006, (71 FR 48947—48948), Research Triangle Institute, Kenneth H. Davis, Jr., Hermann Building, P.O. Box 12194, East Institute Drive, Research Triangle, North Carolina 27709, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug Schedule Marihuana (7360) ......................... Cocaine (9041) ............................. I II jlentini on PROD1PC65 with NOTICES The Institute will manufacture small quantities of cocaine and marihuana derivatives for use by their customers in analytical kits, reagents, and reference standards as directed by NIDA. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Research Triangle Institute to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Research Triangle Institute to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: December 14, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–21872 Filed 12–21–06; 8:45 am] DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Drug Enforcement Administration National Institute of Corrections Manufacturer of Controlled Substances Notice of Registration Solicitation for a Cooperative Agreement—Transition From Jail to the Community (TJC) By Notice dated August 7, 2006, and published in the Federal Register on August 15, 2006, (71 FR 46922), Rhodes Technologies, 498 Washington Street, Coventry, Rhode Island 02816, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: AGENCY: Drug Schedule Tetrahydrocannabinols (7370) ..... Methylphenidate (1724) ................ Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Thebaine (9333) ........................... Noroxymorphone (9668) .............. Fentanyl (9801) ............................ 19:31 Dec 21, 2006 Jkt 211001 I II II II II II II II II II The company plans to manufacture the listed controlled substances in bulk for conversion and sale to dosage form manufacturers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Rhodes Technologies to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Rhodes Technologies to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: December 14, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–21877 Filed 12–21–06; 8:45 am] BILLING CODE 4410–09–P BILLING CODE 4410–09–P VerDate Aug<31>2005 77067 PO 00000 Frm 00108 Fmt 4703 Sfmt 4703 National Institute of Corrections, Department of Justice. ACTION: Solicitation for a Cooperative Agreement. SUMMARY: The Department of Justice (DOJ), National Institute of Corrections (NIC) announces the availability of funds in FY 2007 for a cooperative agreement to initiate the project ‘‘Transition From Jail to the Community’’ (TJC). A cooperative agreement is a form of assistance relationship where NIC is substantially involved during the performance of the award. An award will be made to an organization who will, in concert with NIC, identify the method and approach in developing a jail/community transition program. An 18-month cooperative agreement award will be made to an organization that will help NIC design a jail/ community transition model that will enhance the likelihood that persons released from jails do not commit crimes following release. Ultimately, the transition model will be implemented in a limited number of localities, the impact will be evaluated and knowledge will be shared broadly about what has been learned through focused assistance to those jurisdictions. During the initial award, the model will be developed, and two jurisdictions will be selected to begin testing it before expanding assistance (phase II) to include approximately four additional jurisdictions. Depending on the successful applicant’s work plan, it is anticipated that phase II work will begin as a late task during this initial award or as an early task in what, future funding permitting, will be a subsequent implementation award to the same or different cooperative agreement awardee. No local jurisdictions have been identified as participants. NIC will make participant selections with the awardee at an appropriate point in the approved work plan. NIC views this effort as a comprehensive system change effort that could reasonably take jurisdictions at least two years to implement. DATES: The application must be received by 4 p.m. on Thursday, February 1, 2007. ADDRESSES: Mailed applications must be sent to: Director, National Institute of Corrections, 320 First Street, NW., Room E:\FR\FM\22DEN1.SGM 22DEN1

Agencies

[Federal Register Volume 71, Number 246 (Friday, December 22, 2006)]
[Notices]
[Page 77067]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-21872]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances Notice of Registration

    By Notice dated August 15, 2006, and published in the Federal 
Register on August 22, 2006, (71 FR 48947--48948), Research Triangle 
Institute, Kenneth H. Davis, Jr., Hermann Building, P.O. Box 12194, 
East Institute Drive, Research Triangle, North Carolina 27709, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of the basic classes of controlled 
substances listed in schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Marihuana (7360)...........................  I
Cocaine (9041).............................  II
------------------------------------------------------------------------

    The Institute will manufacture small quantities of cocaine and 
marihuana derivatives for use by their customers in analytical kits, 
reagents, and reference standards as directed by NIDA.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Research Triangle Institute to manufacture the listed basic classes of 
controlled substances is consistent with the public interest at this 
time. DEA has investigated Research Triangle Institute to ensure that 
the company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 
21 CFR 1301.33, the above named company is granted registration as a 
bulk manufacturer of the basic classes of controlled substances listed.

    Dated: December 14, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E6-21872 Filed 12-21-06; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.